U.S. Pharmaceuticals & Biotech Most Popular Stocks

CareDx

Market Cap: US$801.6m

Engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally.

ProKidney

Market Cap: US$800.4m

A clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.

Rezolute

Market Cap: US$800.0m

A late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.

Relay Therapeutics

Market Cap: US$779.3m

Operates as a clinical-stage precision medicines company.

Iovance Biotherapeutics

Market Cap: US$767.1m

A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.

Niagen Bioscience

Market Cap: US$760.8m

Operates as a bioscience company engages in developing healthy aging products.

Septerna

Market Cap: US$753.9m

A clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.

Mind Medicine (MindMed)

Market Cap: US$747.2m

A clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.

Xencor

Market Cap: US$746.8m

A clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer.

Savara

Market Cap: US$739.5m

A clinical stage biopharmaceutical company, focuses on rare respiratory diseases.

Akebia Therapeutics

Market Cap: US$734.5m

A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.

Vir Biotechnology

Market Cap: US$730.7m

A clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.

Prime Medicine

Market Cap: US$728.9m

A biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States.

Kura Oncology

Market Cap: US$727.4m

A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.

Anavex Life Sciences

Market Cap: US$724.9m

Operates as a biopharmaceutical company.

ArriVent BioPharma

Market Cap: US$724.6m

A clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.

Myriad Genetics

Market Cap: US$718.3m

A molecular diagnostic testing and precision medicine company, develops and provides molecular tests.

Theravance Biopharma

Market Cap: US$707.6m

A biopharmaceutical company, develops and commercializes of medicines in the United States.

Day One Biopharmaceuticals

Market Cap: US$703.7m

A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.

Maravai LifeSciences Holdings

Market Cap: US$694.6m

A life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.

Terns Pharmaceuticals

Market Cap: US$688.7m

A clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity.

Elite Pharmaceuticals

Market Cap: US$681.6m

A specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals.

Tyra Biosciences

Market Cap: US$680.1m

A clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.

Gossamer Bio

Market Cap: US$679.9m

A clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.

MBX Biosciences

Market Cap: US$675.2m

A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.

Gyre Therapeutics

Market Cap: US$669.4m

A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.

MeiraGTx Holdings

Market Cap: US$666.9m

A clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases.

Nurix Therapeutics

Market Cap: US$665.1m

A clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.

SNDL

Market Cap: US$661.4m

Engages in the production, distribution, and sale of cannabis products for the adult-use market in Canada.

Aquestive Therapeutics

Market Cap: US$655.7m

Operates as a pharmaceutical company in the United States and internationally.

KalVista Pharmaceuticals

Market Cap: US$653.3m

A biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.

Palvella Therapeutics

Market Cap: US$651.1m

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

Keros Therapeutics

Market Cap: US$639.7m

A clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.

Ginkgo Bioworks Holdings

Market Cap: US$639.1m

Develops a platform for cell programming in the United States.

SIGA Technologies

Market Cap: US$638.0m

A commercial-stage pharmaceutical company, focuses on the health security market in the United States.

Organogenesis Holdings

Market Cap: US$621.6m

A regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.